http://www.docguide.com/news/content...2570C0004A7FEE
Early research that demonstrated frequent loss of PTEN and anti-tumor activity induced with mTOR inhibition led Dr. Oza and colleagues to examine temsirolimus in women with endometrial cancer.
The research team evaluated a cohort of women with recurrent or metastatic endometrial cancer who had not received chemotherapy but had been treated with up to one prior line of hormonal therapy. The 18 women received temsirolimus at a dose of 25 mg weekly for a median of 24 weeks.
Results show that 31% of 16 evaluable women had a confirmed partial response; 63% had stable disease as best response; and 6% had progressive disease.
"It's very encouraging to see such a high level of activity at this early stage," Dr. Oza said. "The results are equivalent to those of currently used cytotoxic chemotherapy. It's really a stunning result."